UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 77

Sortiert nach

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

The Journal of clinical investigation, 2014-02, Vol.124 (2), p.499-508

2014

Volltextzugriff (PDF)

Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

Diabetes care, 2014-05, Vol.37 (5), p.1480-1483

2014

Volltextzugriff (PDF)

Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes

American journal of kidney diseases, 2015-09, Vol.66 (3), p.441-449

2015

Volltextzugriff (PDF)

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2013-10, Vol.382 (9902), p.1413-1423

2013

Volltextzugriff (PDF)

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

Cardiovascular diabetology, 2012-01, Vol.11 (1), p.3-3

2012

Volltextzugriff (PDF)

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)

Diabetes & vascular disease research, 2015-05, Vol.12 (3), p.164-174

2015

Volltextzugriff (PDF)

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

Cardiovascular diabetology, 2014-06, Vol.13 (1), p.102-102

2014

Volltextzugriff (PDF)

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus

Clinical therapeutics, 2015-08, Vol.37 (8), p.1773-1788.e1

2015

Volltextzugriff (PDF)

Pharmacokinetics of linagliptin in subjects with hepatic impairment

British journal of clinical pharmacology, 2012-07, Vol.74 (1), p.75-85

2012

Volltextzugriff (PDF)

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA ® ): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

Cardiovascular diabetology, 2018-03, Vol.17 (1), p.39-39, Article 39

2018

Volltextzugriff (PDF)

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes

PloS one, 2015-11, Vol.10 (11), p.e0141085-e0141085

2015

Volltextzugriff (PDF)

Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction

Diabetes care, 2013-11, Vol.36 (11), p.3460-3468

2013

Volltextzugriff (PDF)

Pharmacodynamics, safety, tolerability and pharmacokinetics of a single oral dose of an engineered phenylalanine ammonia-lyase in patients with phenylketonuria

Molecular genetics and metabolism reports, 2023-12, Vol.37, p.101012-101012, Article 101012

2023

Volltextzugriff (PDF)

Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis

Canadian journal of diabetes, 2016-02, Vol.40 (1), p.50-57

2016

Volltextzugriff (PDF)

Efficacy and Tolerability of Linagliptin Added to a Sulfonylurea Regimen in Patients With Inadequately Controlled Type 2 Diabetes Mellitus: An 18-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Clinical therapeutics, 2012-09, Vol.34 (9), p.1909-1919.e15

2012

Volltextzugriff (PDF)

Efficacy and Safety of Linagliptin in Subjects With Long-standing Type 2 Diabetes Mellitus (>10 Years): Evidence From Pooled Data of Randomized, Double-blind, Placebo-controlled, Phase III Trials

Clinical therapeutics, 2014-11, Vol.36 (11), p.1595-1605

2014

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

Diabetes care, 2013-02, Vol.36 (2), p.237-244

2013

Volltextzugriff (PDF)

Assessment of the Pharmacokinetic Interaction between the Novel DPP-4 Inhibitor Linagliptin and a Sulfonylurea, Glyburide, in Healthy Subjects

DRUG METABOLISM AND PHARMACOKINETICS, 2011-01, Vol.26 (2), p.123-129

2011

Volltextzugriff (PDF)

A Randomized, Open-Label, Crossover Study Evaluating the Effect of Food on the Relative Bioavailability of Linagliptin in Healthy Subjects

Clinical therapeutics, 2011-08, Vol.33 (8), p.1096-1103

2011

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus

British journal of clinical pharmacology, 2013-09, Vol.76 (3), p.445-454

2013

Volltextzugriff (PDF)

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A ≥52-week randomized, double-blind study

Diabetes care, 2013-12, Vol.36 (12), p.3875-3881

2013

Volltextzugriff (PDF)

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects

Clinical therapeutics, 2010-06, Vol.32 (6), p.1188-1204

2010

Volltextzugriff (PDF)

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

Cardiovascular diabetology, 2014-01, Vol.13 (1), p.28-28

2014

Volltextzugriff (PDF)

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

The Lancet (British edition), 2012-08, Vol.380 (9840), p.475-483

2012

Volltextzugriff (PDF)

Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients

Clinical therapeutics, 2011-07, Vol.33 (7), p.973-989

2011

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(77)

Sprache

Englisch
(77)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Science & Technology
(59)
Life Sciences & Biomedicine
(58)
Humans
(56)
Male
(47)
Female
(46)
Diabetes Mellitus, Type 2 - Drug Therapy
(45)
Linagliptin
(38)
Middle Aged
(35)
Aged
(33)
Endocrinology & Metabolism
(30)
Hypoglycemic Agents - Therapeutic Use
(28)
Diabetes
(27)
Adult
(26)
Double-Blind Method
(24)
Dipeptidyl-Peptidase Iv Inhibitors - Therapeutic Use
(22)
Treatment Outcome
(22)
Type 2 Diabetes
(22)
Diabetes Mellitus, Type 2 - Blood
(19)
Hypoglycemic Agents - Adverse Effects
(18)
Purines - Therapeutic Use
(18)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus

Pharmacokinetics of linagliptin in subjects with hepatic impairment

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA ® ): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes

Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction

Pharmacodynamics, safety, tolerability and pharmacokinetics of a single oral dose of an engineered phenylalanine ammonia-lyase in patients with phenylketonuria

Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis

Efficacy and Tolerability of Linagliptin Added to a Sulfonylurea Regimen in Patients With Inadequately Controlled Type 2 Diabetes Mellitus: An 18-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Efficacy and Safety of Linagliptin in Subjects With Long-standing Type 2 Diabetes Mellitus (>10 Years): Evidence From Pooled Data of Randomized, Double-blind, Placebo-controlled, Phase III Trials

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

Assessment of the Pharmacokinetic Interaction between the Novel DPP-4 Inhibitor Linagliptin and a Sulfonylurea, Glyburide, in Healthy Subjects

A Randomized, Open-Label, Crossover Study Evaluating the Effect of Food on the Relative Bioavailability of Linagliptin in Healthy Subjects

Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A ≥52-week randomized, double-blind study

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients

Suchergebnisse filtern